Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

A recent investigation by The New York Times revealed that two pharmaceutical companies, Eisai and Eli Lilly, withheld critical genetic risk information from volunteers during clinical trials for ...

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's ...

Weaver Capital Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.0% in the 3rd quarter ...

Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

Eli Lilly And Co’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 34.50% and a profit margin of 18.86%, with a gross margin of 23.36%. The ...